Details

Autor(en) / Beteiligte

• McBane, Sarah E.
• Dopp, Anna L.
• Abe, Andrew
• Benavides, Sandra
• Chester, Elizabeth A.
• Dixon, Dave L.
• Dunn, Michaelia
• Johnson, Melissa D.
• Nigro, Sarah J.
• Rothrock-Christian, Tracie
• Schwartz, Amy H.
• Thrasher, Kim
• Walker, Scot

Titel

Collaborative Drug Therapy Management and Comprehensive Medication Management-2015

Ist Teil von

• Pharmacotherapy, 2015-04, Vol.35 (4), p.e39-e50

Ort / Verlag

United States: Blackwell Publishing Ltd

Erscheinungsjahr

2015

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• The American College of Clinical Pharmacy (ACCP) previously published position statements on collaborative drug therapy management (CDTM) in 1997 and 2003. Since 2003, significant federal and state legislation addressing CDTM has evolved and expanded throughout the United States. CDTM is well suited to facilitate the delivery of comprehensive medication management (CMM) by clinical pharmacists. CMM, defined by ACCP as a core component of the standards of practice for clinical pharmacists, is designed to optimize medication‐related outcomes in collaborative practice environments. New models of care delivery emphasize patient‐centered, team‐based care and increasingly link payment to the achievement of positive economic, clinical, and humanistic outcomes. Hence clinical pharmacists practicing under CDTM agreements or through other privileging processes are well positioned to provide CMM. The economic value of clinical pharmacists in team‐based settings is well documented. However, patient access to CMM remains limited due to lack of payer recognition of the value of clinical pharmacists in collaborative care settings and current health care payment policy. Therefore, the clinical pharmacy discipline must continue to establish and expand its use of CDTM agreements and other collaborative privileging mechanisms to provide CMM. Continued growth in the provision of CMM by appropriately qualified clinical pharmacists in collaborative practice settings will enhance recognition of their positive impact on medication‐related outcomes.